A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Peter Mollee; John Reynolds; Wojciech Janowski; Hang Quach; Philip Campbell; Simon D. Gibbs; Sophie Lee; James D'Rozario; Kerry Taylor; Tara Cochrane; Craig Thomas Wallington-Beddoe; Fiona Kwok; Nicholas Weber; Ian H. Kerridge; Helen Weston; P. Joy Ho; Noemi Horvath; Flora Yuen; Andrew Spencer

doi:10.1182/blood-2021-152500

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Peter Mollee, John Reynolds, Wojciech Janowski, Hang Quach, Philip Campbell, Simon D. Gibbs, Sophie Lee, James D'Rozario, Kerry Taylor, Tara Cochrane, Craig Thomas Wallington-Beddoe, Fiona Kwok, Nicholas Weber, Ian H. Kerridge, Helen Weston, P. Joy Ho, Noemi Horvath, Flora Yuen, Andrew Spencer

College of Medicine and Public Health

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Introduction

Daratumumab, when added to standard of care regimens in relapsed and untreated myeloma, has consistently demonstrated significant improvements in response rates, induction of MRD negative responses and prolonged progression-free survival (PFS) while proving highly tolerable with minor increases in overall regimen toxicity. In non-transplant eligible patients daratumumab has been added in randomized studies to lenalidomide and dexamethasone (Rd) and bortezomib, melphalan and prednisolone (VMP) backbones, but not to the VCD regimen. Furthermore, the randomized studies excluded a significant proportion of patients with comorbidities so the benefit of daratumumab in a frail, elderly myeloma population remains untested.

Original language	English
Article number	2728
Number of pages	2
Journal	Blood
Volume	138
Issue number	Supplement 1
DOIs	https://doi.org/10.1182/blood-2021-152500
Publication status	Published - Nov 2021

Keywords

Bortezomib
Cyclophosphamide
Dexamethasone
Daratumumab
Myeloma
VCDD
VCD

Access to Document

10.1182/blood-2021-152500Licence: In Copyright

Fingerprint

Dive into the research topics of 'A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)'. Together they form a unique fingerprint.

Cite this

Mollee, P., Reynolds, J., Janowski, W., Quach, H., Campbell, P., Gibbs, S. D., Lee, S., D'Rozario, J., Taylor, K., Cochrane, T., Wallington-Beddoe, C. T., Kwok, F., Weber, N., Kerridge, I. H., Weston, H., Ho, P. J., Horvath, N., Yuen, F., & Spencer, A. (2021). A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). Blood, 138(Supplement 1), Article 2728. https://doi.org/10.1182/blood-2021-152500

@article{a2194cb9e7f9405d9dca934d15d667ee,

title = "A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)",

abstract = "IntroductionDaratumumab, when added to standard of care regimens in relapsed and untreated myeloma, has consistently demonstrated significant improvements in response rates, induction of MRD negative responses and prolonged progression-free survival (PFS) while proving highly tolerable with minor increases in overall regimen toxicity. In non-transplant eligible patients daratumumab has been added in randomized studies to lenalidomide and dexamethasone (Rd) and bortezomib, melphalan and prednisolone (VMP) backbones, but not to the VCD regimen. Furthermore, the randomized studies excluded a significant proportion of patients with comorbidities so the benefit of daratumumab in a frail, elderly myeloma population remains untested.",

keywords = "Bortezomib, Cyclophosphamide, Dexamethasone, Daratumumab, Myeloma, VCDD, VCD",

author = "Peter Mollee and John Reynolds and Wojciech Janowski and Hang Quach and Philip Campbell and Gibbs, {Simon D.} and Sophie Lee and James D'Rozario and Kerry Taylor and Tara Cochrane and Wallington-Beddoe, {Craig Thomas} and Fiona Kwok and Nicholas Weber and Kerridge, {Ian H.} and Helen Weston and Ho, {P. Joy} and Noemi Horvath and Flora Yuen and Andrew Spencer",

year = "2021",

month = nov,

doi = "10.1182/blood-2021-152500",

language = "English",

volume = "138",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "Supplement 1",

}

Mollee, P, Reynolds, J, Janowski, W, Quach, H, Campbell, P, Gibbs, SD, Lee, S, D'Rozario, J, Taylor, K, Cochrane, T, Wallington-Beddoe, CT, Kwok, F, Weber, N, Kerridge, IH, Weston, H, Ho, PJ, Horvath, N, Yuen, F & Spencer, A 2021, 'A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)', Blood, vol. 138, no. Supplement 1, 2728. https://doi.org/10.1182/blood-2021-152500

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). / Mollee, Peter; Reynolds, John; Janowski, Wojciech et al.
In: Blood, Vol. 138, No. Supplement 1, 2728, 11.2021.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

AU - Mollee, Peter

AU - Reynolds, John

AU - Janowski, Wojciech

AU - Quach, Hang

AU - Campbell, Philip

AU - Gibbs, Simon D.

AU - Lee, Sophie

AU - D'Rozario, James

AU - Taylor, Kerry

AU - Cochrane, Tara

AU - Wallington-Beddoe, Craig Thomas

AU - Kwok, Fiona

AU - Weber, Nicholas

AU - Kerridge, Ian H.

AU - Weston, Helen

AU - Ho, P. Joy

AU - Horvath, Noemi

AU - Yuen, Flora

AU - Spencer, Andrew

PY - 2021/11

Y1 - 2021/11

N2 - IntroductionDaratumumab, when added to standard of care regimens in relapsed and untreated myeloma, has consistently demonstrated significant improvements in response rates, induction of MRD negative responses and prolonged progression-free survival (PFS) while proving highly tolerable with minor increases in overall regimen toxicity. In non-transplant eligible patients daratumumab has been added in randomized studies to lenalidomide and dexamethasone (Rd) and bortezomib, melphalan and prednisolone (VMP) backbones, but not to the VCD regimen. Furthermore, the randomized studies excluded a significant proportion of patients with comorbidities so the benefit of daratumumab in a frail, elderly myeloma population remains untested.

AB - IntroductionDaratumumab, when added to standard of care regimens in relapsed and untreated myeloma, has consistently demonstrated significant improvements in response rates, induction of MRD negative responses and prolonged progression-free survival (PFS) while proving highly tolerable with minor increases in overall regimen toxicity. In non-transplant eligible patients daratumumab has been added in randomized studies to lenalidomide and dexamethasone (Rd) and bortezomib, melphalan and prednisolone (VMP) backbones, but not to the VCD regimen. Furthermore, the randomized studies excluded a significant proportion of patients with comorbidities so the benefit of daratumumab in a frail, elderly myeloma population remains untested.

KW - Bortezomib

KW - Cyclophosphamide

KW - Dexamethasone

KW - Daratumumab

KW - Myeloma

KW - VCDD

KW - VCD

U2 - 10.1182/blood-2021-152500

DO - 10.1182/blood-2021-152500

M3 - Meeting Abstract

SN - 0006-4971

VL - 138

JO - Blood

JF - Blood

IS - Supplement 1

M1 - 2728

ER -

Mollee P, Reynolds J, Janowski W, Quach H, Campbell P, Gibbs SD et al. A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). Blood. 2021 Nov;138(Supplement 1):2728. doi: 10.1182/blood-2021-152500